반려동물용 의약품 시장 : 시장 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of companion animal pharmaceuticals Market

The global companion animal pharmaceuticals market size was valued at USD 21.38 billion in 2025 and is projected to grow from USD 22.60 billion in 2026 to USD 38.87 billion by 2034, exhibiting a CAGR of 7.02% during the forecast period. North America dominated the global market with a 40.73% market share in 2025, driven by high pet ownership rates, increasing veterinary healthcare expenditure, and growing demand for advanced pet therapeutics.

Companion animal pharmaceuticals include prescription medicines, vaccines, parasiticides, dermatology treatments, pain management products, anti-infectives, and chronic disease therapies designed for pets such as dogs, cats, birds, and other companion animals. Rising pet humanization, increasing awareness of preventive healthcare, and growing demand for premium veterinary treatments are major factors contributing to market expansion. Furthermore, continuous innovation in long-acting therapies, monoclonal antibodies, and broad-spectrum parasite control products is accelerating industry growth.

Market Trends

Rising Pet Humanization Driving Premium Therapeutic Demand

One of the most influential trends in the companion animal pharmaceuticals market is the growing humanization of pets. Pet owners increasingly consider animals as family members and are willing to invest in advanced treatments that improve quality of life and long-term health outcomes.

This trend is encouraging pharmaceutical companies to develop innovative therapies for chronic conditions such as osteoarthritis, allergic dermatitis, and kidney disease. The growing adoption of long-acting biologics, monoclonal antibodies, and specialty therapeutics is expanding the market beyond traditional preventive care products and creating new revenue opportunities for manufacturers.

Market Drivers

Rising Pet Ownership Supporting Market Expansion

The steady increase in global pet ownership is a primary factor driving companion animal pharmaceuticals market growth. As the number of companion animals rises, demand for routine veterinary care, vaccinations, parasite control, and chronic disease management also increases.

Pet owners are increasingly seeking convenient, effective, and comprehensive treatment options for their animals. Pharmaceutical companies continue to introduce innovative products with broader disease coverage and improved dosing convenience, further strengthening market demand. Regulatory approvals for new therapies and expanded product labels are also contributing to sustained market growth.

Market Restraints

High Veterinary Care and Medication Costs

The increasing cost of veterinary services and pharmaceutical treatments remains a major restraint for market growth. Many pet owners are becoming more price-sensitive and may delay veterinary visits or discontinue long-term treatment plans due to financial concerns.

Higher treatment costs can particularly affect chronic disease management, where ongoing medication and regular monitoring are required. As affordability challenges increase, treatment adherence may decline, impacting overall pharmaceutical sales growth.

Market Opportunities

Expanding Pet Insurance Coverage

Growing adoption of pet insurance is creating significant opportunities for companion animal pharmaceutical manufacturers. Insurance coverage helps reduce the financial burden associated with diagnostics, medications, surgeries, and long-term disease management.

As insurance penetration increases, pet owners are more likely to approve advanced treatments, specialty medicines, and preventive care programs. This trend is expected to improve treatment continuity and support higher utilization of branded veterinary pharmaceuticals.

Market Challenges

Complex Regulatory Approval Requirements

Companion animal pharmaceutical companies face significant challenges related to regulatory compliance and product approval processes. Veterinary medicines must meet strict standards for safety, efficacy, manufacturing quality, and post-market monitoring before commercialization.

The complexity of regulatory pathways often increases development costs and extends product launch timelines. These challenges can slow innovation and delay the introduction of new therapies into the market.

Segment Analysis

By Product

The veterinary drugs segment accounted for the largest market share in 2025 due to its extensive use in managing pain, dermatological conditions, parasitic infections, cardiovascular disorders, and chronic diseases. Continuous demand for therapeutic medications supports the segment's dominance.

The veterinary vaccines segment is expected to grow at a CAGR of 9.26% during the forecast period due to increasing focus on preventive animal healthcare.

By Animal Type

The canine segment dominated the market in 2025 owing to higher veterinary visit frequency, stronger adoption of preventive care products, and wider availability of approved pharmaceutical treatments.

The feline segment is projected to grow at a CAGR of 8.00% through 2034 as awareness regarding cat healthcare continues to increase globally.

By Route of Administration

The oral segment is expected to maintain market leadership throughout the forecast period. Oral tablets and chewable formulations offer greater convenience, improved compliance, and easier administration for pet owners managing long-term therapies.

The aerosol segment is anticipated to grow at a CAGR of 8.70% during the forecast period.

By Distribution Channel

The veterinary hospitals segment held the largest market share in 2025 due to their critical role in diagnosis, prescription, treatment monitoring, and product recommendation.

The pharmacies and drug stores segment is projected to expand at a CAGR of 8.70% through 2034, supported by increasing accessibility of veterinary medicines.

Regional Outlook

North America

North America remained the leading regional market with a valuation of USD 8.71 billion in 2025 and is projected to maintain strong growth due to high pet ownership, rising veterinary spending, and widespread adoption of advanced animal healthcare products.

Europe

Europe is projected to reach USD 5.60 billion in 2026 and grow at a CAGR of 6.73% during the forecast period. Strong pet ownership rates and well-established veterinary healthcare systems support market expansion.

Asia Pacific

Asia Pacific is expected to reach USD 3.99 billion in 2026 and emerge as one of the fastest-growing regions. Rising disposable incomes, increasing pet adoption, and expanding veterinary infrastructure are driving growth across major countries such as China, Japan, and India.

Latin America and Middle East & Africa

Latin America is projected to reach USD 2.37 billion in 2026, while the GCC market is expected to attain USD 0.38 billion. Growing pet healthcare awareness and improving veterinary services continue to support regional development.

Competitive Landscape

The companion animal pharmaceuticals market is highly consolidated, with major companies focusing on product innovation, acquisitions, strategic collaborations, and regulatory approvals to strengthen their market positions. Leading market participants include Zoetis Inc., Elanco, Boehringer Ingelheim Animal Health, Merck Animal Health, Virbac, Vetoquinol S.A., Ceva Sante Animale, Norbrook Laboratories, Chanelle Pharma, and Bimeda Animal Health Ltd.

Recent developments include approvals for innovative treatments targeting osteoarthritis, allergic dermatitis, chronic kidney disease, otitis externa, and parasite prevention. Companies are also investing in genomics, biologics, and personalized veterinary healthcare solutions to expand their product portfolios.

Conclusion

The companion animal pharmaceuticals market is witnessing steady growth as pet ownership rises and animals increasingly receive healthcare comparable to human family members. Growing demand for preventive care, chronic disease management, pain relief therapies, vaccines, and advanced biologics is supporting long-term market expansion. With the market projected to grow from USD 21.38 billion in 2025 to USD 38.87 billion by 2034, supported by increasing pet healthcare spending, expanding insurance coverage, and continuous pharmaceutical innovation, the industry is expected to remain one of the fastest-evolving segments within the global animal healthcare sector.

Segmentation By Product, Animal Type, Route of Administration, Distribution Channel, and Region

By Product * Veterinary Drugs

• Anti-infectives
• Anti-inflammatory
• Parasiticides
• Others
• Veterinary Vaccines
  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Animal Type * Feline

• Canine
• Avian
• Others

By Route of Administration * Oral

• Parenteral
• Topical
• Aerosol
• Others

By Distribution Channel * Veterinary Hospitals

• Veterinary Clinics
• Pharmacies & Drug Stores
• Others

By Region * North America (By Product, Animal Type, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Veterinary Diseases, By Key Indication, By Key Countries /Regions
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Veterinary Drugs
    • 5.1.1.1. Anti-infectives
    • 5.1.1.2. Anti-inflammatory
    • 5.1.1.3. Parasiticides
    • 5.1.1.4. Others
  • 5.1.2. Veterinary Vaccines
    • 5.1.2.1. Inactivated
    • 5.1.2.2. Live Attenuated
    • 5.1.2.3. Recombinant
    • 5.1.2.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Animal Type
  • 5.2.1. Feline
  • 5.2.2. Canine
  • 5.2.3. Avian
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Topical
  • 5.3.4. Aerosol
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Veterinary Hospitals
  • 5.4.2. Veterinary Clinics
  • 5.4.3. Pharmacies & Drug Stores
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Veterinary Drugs
    • 6.1.1.1. Anti-infectives
    • 6.1.1.2. Anti-inflammatory
    • 6.1.1.3. Parasiticides
    • 6.1.1.4. Others
  • 6.1.2. Veterinary Vaccines
    • 6.1.2.1. Inactivated
    • 6.1.2.2. Live Attenuated
    • 6.1.2.3. Recombinant
    • 6.1.2.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Animal Type
  • 6.2.1. Feline
  • 6.2.2. Canine
  • 6.2.3. Avian
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Topical
  • 6.3.4. Aerosol
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Veterinary Hospitals
  • 6.4.2. Veterinary Clinics
  • 6.4.3. Pharmacies & Drug Stores
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Veterinary Drugs
    • 7.1.1.1. Anti-infectives
    • 7.1.1.2. Anti-inflammatory
    • 7.1.1.3. Parasiticides
    • 7.1.1.4. Others
  • 7.1.2. Veterinary Vaccines
    • 7.1.2.1. Inactivated
    • 7.1.2.2. Live Attenuated
    • 7.1.2.3. Recombinant
    • 7.1.2.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Animal Type
  • 7.2.1. Feline
  • 7.2.2. Canine
  • 7.2.3. Avian
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Topical
  • 7.3.4. Aerosol
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Veterinary Hospitals
  • 7.4.2. Veterinary Clinics
  • 7.4.3. Pharmacies & Drug Stores
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Veterinary Drugs
    • 8.1.1.1. Anti-infectives
    • 8.1.1.2. Anti-inflammatory
    • 8.1.1.3. Parasiticides
    • 8.1.1.4. Others
  • 8.1.2. Veterinary Vaccines
    • 8.1.2.1. Inactivated
    • 8.1.2.2. Live Attenuated
    • 8.1.2.3. Recombinant
    • 8.1.2.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Animal Type
  • 8.2.1. Feline
  • 8.2.2. Canine
  • 8.2.3. Avian
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Topical
  • 8.3.4. Aerosol
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Veterinary Hospitals
  • 8.4.2. Veterinary Clinics
  • 8.4.3. Pharmacies & Drug Stores
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Southeast Asia
  • 8.5.5. Australia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Veterinary Drugs
    • 9.1.1.1. Anti-infectives
    • 9.1.1.2. Anti-inflammatory
    • 9.1.1.3. Parasiticides
    • 9.1.1.4. Others
  • 9.1.2. Veterinary Vaccines
    • 9.1.2.1. Inactivated
    • 9.1.2.2. Live Attenuated
    • 9.1.2.3. Recombinant
    • 9.1.2.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Animal Type
  • 9.2.1. Feline
  • 9.2.2. Canine
  • 9.2.3. Avian
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Topical
  • 9.3.4. Aerosol
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Veterinary Hospitals
  • 9.4.2. Veterinary Clinics
  • 9.4.3. Pharmacies & Drug Stores
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Companion Animal Pharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Veterinary Drugs
    • 10.1.1.1. Anti-infectives
    • 10.1.1.2. Anti-inflammatory
    • 10.1.1.3. Parasiticides
    • 10.1.1.4. Others
  • 10.1.2. Veterinary Vaccines
    • 10.1.2.1. Inactivated
    • 10.1.2.2. Live Attenuated
    • 10.1.2.3. Recombinant
    • 10.1.2.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Animal Type
  • 10.2.1. Feline
  • 10.2.2. Canine
  • 10.2.3. Avian
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Topical
  • 10.3.4. Aerosol
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Veterinary Hospitals
  • 10.4.2. Veterinary Clinics
  • 10.4.3. Pharmacies & Drug Stores
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Zoetis Inc.
  • 11.2.2. Elanco
  • 11.2.3. Boehringer Ingelheim Animal Health
  • 11.2.4. Merck Animal Health
  • 11.2.5. Virbac
  • 11.2.6. Vetoquinol S.A.
  • 11.2.7. Ceva Sante Animale
  • 11.2.8. Norbrook Laboratories Limited
  • 11.2.9. Chanelle Pharma
  • 11.2.10. Bimeda Animal Health Ltd.